Purpose: The objective of this study was to formalize and automate quality assurance (QA) in radiation oncology. Quality assurance in radiation oncology entails a multistep verification of complex, personalized radiation plans to treat cancer involving an interdisciplinary team and high technology, multivendor software and hardware systems. We addressed the pretreatment physics chart review (TPCR) using methods from graph theory and constraint programming to study the effect of dependencies between variables and automatically identify logical inconsistencies and how they propagate.
Materials And Methods: We used a modular approach to decompose the TPCR process into tractable units comprising subprocesses, modules and variables. Modules represented the main software entities comprised in the radiation treatment planning workflow and subprocesses grouped the checks to be performed by functionality. Module-associated variables served as inputs to the subprocesses. Relationships between variables were modeled by means of a directed graph. The detection of errors, in the form of inconsistencies, was formalized as a constraint satisfaction problem whereby checks were encoded as logical formulae. The sequence in which subprocesses were visited was described in an activity diagram.
Results: The comprehensive model for the TPCR process comprised 5 modules, 19 subprocesses and 346 variables, 225 of which were distinct. Modules included "Treatment Planning System" and "Record and Verify System." Subprocesses included "Dose Prescription," "Documents," "CT Integrity," "Anatomical Contours," "Beam Configuration," "Dose Calculation," "3D Dose Distribution Quality," and "Treatment Approval." Variable inconsistencies, and their source and propagation were determined by checking for constraint violation and through graph traversal. Impact scores, obtained through graph traversal, combined with severity scores associated with an inconsistency, allowed risk assessment.
Conclusions: Directed graphs combined with constraint programming hold promise for formalizing complex QA processes in radiation oncology, performing risk assessment and automating the TPCR process. Though complex, the process is tractable.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mp.14666 | DOI Listing |
Cureus
December 2024
Hematology/Oncology, University of Kansas Medical Center, Kansas City, USA.
A 58-year-old male, with a history of human immunodeficiency virus (HIV) and stage 4 left frontotemporal squamous cell carcinoma (SCC), presented with new-onset neck pain. He was diagnosed with HIV five years prior. The patient had a cluster of differentiation 4 (CD4) count of 53 cells/mm³ and a high viral load, later suppressed with bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).
View Article and Find Full Text PDFJ Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFKidney Med
January 2025
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Oncol Lett
March 2025
State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, P.R. China.
High-intensity focused ultrasound thermal ablation (HIFU) is a novel non-invasive technique in the treatment of liver metastases (LIM) that allows focal destruction and is not affected by dose limits. This retrospective study aimed to explore the efficacy of HIFU in improving survival and the safety of the method in newly diagnosed patients with cancer with LIM who received first-line immune checkpoint inhibitor (ICI) therapy. Between January 2018 and December 2023, data from 438 newly diagnosed patients with cancer and LIM who were treated at Mianyang Central Hospital (Mianyang, China) were reviewed.
View Article and Find Full Text PDFInt J Surg
December 2024
Department of Radiology, Changhai Hospital.
Background: Extrapancreatic perineural invasion (EPNI) increases the risk of postoperative recurrence in pancreatic ductal adenocarcinoma (PDAC). This study aimed to develop and validate a computed tomography (CT)-based, fully automated preoperative artificial intelligence (AI) model to predict EPNI in patients with PDAC.
Methods: The authors retrospectively enrolled 1065 patients from two Shanghai hospitals between June 2014 and April 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!